Eloralintide
Sponsors
Eli Lilly & Co., Eli Lilly and Company
Conditions
Diabetes Mellitus, Type 2Healthy VolunteersObesityObstructiveOsteoarthritisOverweightOverweight or ObesitySleep Apnea
Phase 1
A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
CompletedNCT06916091
Start: 2025-04-21End: 2025-09-09Updated: 2025-11-19
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
CompletedNCT06916065
Start: 2025-04-09End: 2026-01-19Updated: 2026-01-30
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
RecruitingNCT07665879
Start: 2026-06-24End: 2027-08-01Target: 115Updated: 2026-07-16
A Study of Eloralintide (LY3841136) in Healthy Participants
RecruitingNCT07701083
Start: 2026-07-20End: 2026-10-01Target: 58Updated: 2026-08-20
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
RecruitingNCT07738614
Start: 2026-07-31End: 2026-12-01Target: 56Updated: 2026-08-20
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
Not yet recruitingNCT07765511
Start: 2026-10-01End: 2027-06-01Target: 60Updated: 2026-08-14
A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight
Not yet recruitingNCT07808060
Start: 2026-09-01End: 2027-06-01Target: 34Updated: 2026-09-08
Phase 2
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
CompletedNCT06230523
Start: 2024-02-05End: 2025-08-14Updated: 2026-06-24
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RecruitingNCT07215559
Start: 2025-10-16End: 2027-05-01Target: 200Updated: 2026-09-08
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
RecruitingNCT07589608
Start: 2026-05-15End: 2028-02-01Target: 400Updated: 2026-08-06
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RecruitingNCT07282600
Start: 2025-12-15End: 2028-02-01Target: 1035Updated: 2026-09-08
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
RecruitingNCT07321886
Start: 2026-02-06End: 2030-07-01Target: 1980Updated: 2026-08-21
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
RecruitingNCT07353931
Start: 2026-02-09End: 2028-05-01Target: 900Updated: 2026-09-08
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
RecruitingNCT07369011
Start: 2026-02-10End: 2028-04-01Target: 800Updated: 2026-09-08
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
RecruitingNCT07392190
Start: 2026-02-10End: 2028-07-01Target: 900Updated: 2026-09-08
J3R-MC-YDAO - A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Moderate to Severe Obstructive Sleep Apnea, and Obesity or Overweight (ENLIGHTEN-3)
Intervention-Specific Appendices (ISAs):
J3R-MC-YSA1: Participants unable or unwilling to use positive airway pressure therapy
J3R-MC-YSA2: Participants treated with positive airway pressure therapy
Not yet recruitingCTIS2025-523769-11-00
Target: 85Updated: 2026-03-20
J3R-MC-YDAG - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes
Not yet recruitingCTIS2025-523657-34-00
Target: 62Updated: 2026-03-27
J3R-MC-YDAN - A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
J3R-MC-YOA1: Intervention-Specific Appendix 1 (ISA1) for Eloralintide in Participants with Osteoarthritis Knee Pain
J3R-MC-YOA2: Intervention-Specific Appendix 2 (ISA2) for Eloralintide in Participants with Osteoarthritis Knee Pain
Not yet recruitingCTIS2025-523768-19-00
Target: 20Updated: 2026-04-02
J3R-MC-YDAL - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Not yet recruitingCTIS2025-523659-73-00
Target: 167Updated: 2026-04-21